This inventor holds 23 USPTO granted patents, plus 7 CIPO patents and 8 EPO patents, primarily in Kinase Inhibitors. Top assignees: Janssen Pharmaceutica Nv, 3-Dimensional Pharmaceuticals, Inc.. Active years: 2006-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
20 out of 2,101 
3 out of 77 Years Active: 2006-2016
Areas of Expertise:
Title: **Shelley K. Ballentine: A Pioneer in Kinase Research and Therapeutics**
Introduction
Shelley K. Ballentine, based in Lansdale, PA, is a prominent inventor known for his substantial contributions to the field of biochemistry and pharmacology. With an impressive portfolio of 23 patents, Ballentine's innovations focus primarily on methods to inhibit kinases and their therapeutic applications in treating various diseases.
Latest Patents
Some of Ballentine's latest patents include groundbreaking methods aimed at inhibiting C-KIT kinase, which plays a critical role in several cell proliferative disorders and cancers. His inventions offer methods for reducing or inhibiting the activity of C-KIT in cells, thereby providing potential treatment options for conditions such as cancers and other related disorders. Another significant patent addresses inhibitors of c-fms kinase, detailing compounds capable of inhibiting specific protein tyrosine kinases. His research aids in treating autoimmune diseases and cancer metastasis, including ovarian cancer, breast cancer, and other malignancies. Additionally, the compounds developed from his research have implications for managing various types of pain and metabolic bone diseases.
Career Highlights
Throughout his career, Shelley K. Ballentine has worked with reputable companies such as Janssen Pharmaceutica and 3-Dimensional Pharmaceuticals, Inc. His work at these organizations has been pivotal in advancing the understanding and treatment options for complex diseases through innovative pharmaceutical formulations.
Collaborations
Ballentine has collaborated with several notable professionals in his field, including Sanath K. Meegalla and Jinsheng Chen. These collaborations have enhanced the research landscape, enabling the development of effective therapeutic strategies that address critical health challenges.
Conclusion
Shelley K. Ballentine's contributions to kinase research and therapeutic innovations reflect his dedication to improving health outcomes through scientific advancements. His patents not only stand as a testament to his innovative spirit but also pave the way for future developments in the treatment of diseases that significantly affect patients' lives. As he continues to explore new avenues in biotechnology, his work remains a valuable asset in the ongoing battle against various health disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile